Fresh analysis indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop conventional lifestyle plans.
Published data in a prominent health publication points out that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using these drugs should be cognizant of the risk of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to original weight within about one and a half years.
Comparing Treatments
The research, which examined dozens of studies involving thousands of patients, contrasted the effects of these new drugs with older methods.
Researchers point out that people who lose weight through lifestyle changes alone usually have a more gradual creep back—approximately 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Doctors believe the mechanism of the drugs is key to understanding the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating far more likely."
A Lifelong Condition?
The NHS recommend the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of relapse, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who state that the findings "highlight the persistent nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the medication describe a intense resurgence of appetite.
"It was like a switch activating and I was suddenly starving," said one woman.
This challenge is exacerbated if users have not adopted sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is greater among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
Finally, experts stress that while these medications are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on ongoing lifestyle support.
